Advancing analytical testing and instrumentation for biopharmaceuticals - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advancing analytical testing and instrumentation for biopharmaceuticals
Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.

Pharmaceutical Technology
Volume 37, Issue 3, pp. 42

In May 2012, Shimazdu launched an improved Accurate Glycan Analyzer 2 (AGA2), which provides a glycan database and the company's AXIMA Resonance, a MALDI (matrix-assisted laser desorption/ionization)–QIT (quadrupole ion trap)–TOF (time of flight) mass spectrometer. The AXIMA Resonance is coupled to a database containing glycan structural information generated from actual MSn spectra to select precursor peaks up to MS4 . The resulting spectra are interpreted to return the most likely glycan structure. The AGA2 was created from biosynthesized glycans and contains well-defined and characterized, biologically relevant, glycans. It also uses common fluorescence-labeling schemes, including 2-aminopyridine, 2-aminobenzoic acid and 2-aminobenzamide, and other types of fluorescence labeling.

In February 2013, Thermo Fisher Scientific expanded its high-content analysis portfolio with three new solutions in cell biology: the Thermo Scientific ArrayScan XTI High Content Analysis (HCA) Reader, Thermo Scientific CellInsight NXT High Content Screening (HCS) Platform, and the Thermo Scientific X1 upgrade for current ArrayScan VTI customers. Each of these products features a large-format, sensitive CCD (charged-coupled device) camera, the Thermo Scientific HCS Studio software suite, and greater processing capabilities. The Thermo Scientific X1 CCD camera, used for high-content analysis, offers improved sensitivity, increased resolution, and a large field of view.

Thermo Fisher Scientific also introduced the Thermo Scientific Dionex GlycanPac AXH-1 HPLC column, which is designed for simultaneous separation of biologically important glycans based on charge, size, and polarity. The column is designed to separate both labeled and native glycans based on the availability of samples. Native glycan separation allows researchers to eliminate the fluorescent labeling step and increase throughput.

In 2012, Agilent Technologies partnered with Spain's Center for Omic Sciences in mass spectrometry and NMR (nuclear magnetic resonance)-based metabolomics and automation for use in integrated systems biology. The Center for Omic Sciences (COS) was established by the Rovira i Virgili University in collaboration with Spain's Technological Center of Nutrition and Health. COS opened in September 2012 and is equipped with instrumentation from Agilent. The COS is a center of excellence where Agilent will demonstrate integrated biology workflows in genomics, proteomics, transcriptomics, lipidomics, and metabolomics.

In November 2012, Bruker launched METALJET, a bright microfocus X-ray source for structural biology applications. METALJET is a source option for D8 VENTURET protein crystallography systems and for NANOSTAR Small Angle X-ray Scattering (SAXS) systems. The METALJET source for Bruker structural biology systems was developed in collaboration with Excillum AB and Incoatec GmbH for use in protein crystallography and SAXS applications.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here